We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XYLO
126
DELISTED
Xylo Technologies
XYLO
$608K 0.04%
+1,743
New +$699K
DRNA
127
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$602K 0.04%
190,000
-10,000
-5% -$31.6K
VXZ
128
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$600K 0.04%
26,500
-23,500
-47% -$579K
KA
129
DELISTED
Kineta, Inc. Common Stock
KA
$586K 0.04%
894
+468
+110% +$333K
VTVT icon
130
vTv Therapeutics
VTVT
$123M
$583K 0.04%
2,935
-160
-5% -$33.4K
ACHN
131
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$574K 0.04%
1,250
-5,113
-80% -$20.6K
SSKN
132
DELISTED
Strata Skin Sciences
SSKN
$571K 0.04%
23,483
+9,323
+66% +$260K
ARMP icon
133
Armata Pharmaceuticals
ARMP
$170M
$570K 0.04%
52,244
+50,066
+2,299% +$1.21M
INDP icon
134
Indaptus Therapeutics
INDP
$239M
$528K 0.03%
41
-189
-82% -$2.29M
VKTX icon
135
Viking Therapeutics
VKTX
$3.89B
$525K 0.03%
+486,491
New +$619K
VIRX
136
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$525K 0.03%
56
+10
+22% +$1.15K
IOVA icon
137
Iovance Biotherapeutics
IOVA
$2.08B
$524K 0.03%
71,251
+11,095
+18% +$70.5K
SGMO
138
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$506K 0.03%
575
+19
+3% +$122
TGTX icon
139
CALL
TG Therapeutics
TGTX
$8.4B
$492K 0.03%
490
– –
MDCO
140
PUT
DELISTED
Medicines Co
MDCO
$483K 0.03%
+127
New +$5.66K
IDXG
141
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$476K 0.03%
+52,982
New +$1.04M
KPRX icon
142
Kiora Pharmaceuticals
KPRX
$11.1M
$473K 0.03%
+64
New +$632K
ABUS icon
143
CALL
Arbutus Biopharma
ABUS
$875M
$472K 0.03%
1,311
+996
+316% +$3.43K
AIM
144
AIM ImmunoTech
AIM
$6.6M
$472K 0.03%
214
-52
-20% -$129K
BPTH
145
DELISTED
Bio-Path Holdings Inc
BPTH
$462K 0.03%
298
+126
+73% +$264K
ALDX icon
146
Aldeyra Therapeutics
ALDX
$95.9M
$454K 0.03%
97,704
-81,923
-46% -$377K
CYTXW
147
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$454K 0.03%
1,262,452
+805
+0.1% +$357
MDCO
148
DELISTED
Medicines Co
MDCO
$447K 0.03%
+11,764
New +$524K
NBSE
149
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$436K 0.03%
1,703
-2,070
-55% -$556K
RIBT
150
DELISTED
RiceBran Technologies
RIBT
$429K 0.03%
44,685
-33,271
-43% -$290K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.